Effect Of Kad‐1229, A Novel Hypoglycaemic Agent, On Plasma Glucose Levels After Meal Load In Type 2 Diabetic Rats

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical and Experimental Pharmacology and Physiology

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1440-1681.2002.03682.xPMID 12010187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of KAD-1229, a Nonsulfonylurea Hypoglycemic Agent, on Plasma Glucose and Insulin in Streptozotocin-Induced Diabetic Dogs

  2001cited by this paper
• Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

  2000cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.

  1999cited by this paper
• Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells.

  1999cited by this paper
• Implicating PARP and NAD+ depletion in type I diabetes

  1999cited by this paper
• Experimental NIDDM: Development of a New Model in Adult Rats Administered Streptozotocin and Nicotinamide

  1998cited by this paper
• Effects of Voglibose on Glycemic Excursions, Insulin Secretion, and Insulin Sensitivity in Non-lnsulin-ireated NIDDM Patients

  1998cited by this paper
• Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (−)‐N‐(trans‐4‐isopropylcyclohexane‐carbonyl)‐d‐phenylalanine (A‐4166)

  1997cited by this paper
• Are animal models of diabetes relevant to the study of the genetics of non-insulin-dependent diabetes in humans?

  1997cited by this paper
• Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.

  1997influential reference
• Effect of a non‐sulphonylurea hypoglycaemic agent, KAD‐1229 on hormone secretion in the isolated perfused pancreas of the rat

  1996cited by this paper
• Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats.

  1995cited by this paper
• Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide.

  1994cited by this paper
• Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell.

  1994cited by this paper
• Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

  1992cited by this paper
• Analysis of Early-Phase Insulin Responses in Nonobese Subjects With Mild Glucose Intolerance

  1992cited by this paper
• Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.

  1991cited by this paper
• Treatment of NIDDM patients with peroral antidiabetic drugs

  1990cited by this paper
• Symptomatic Hypoglycemia in NIDDM Patients Treated With Oral Hypoglycemic Agents

  1989cited by this paper
• Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.

  1988cited by this paper
• Sulphonylureas and hypoglycaemia

  1988cited by this paper
• Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents.

  1986cited by this paper
• Incidence of severe sideeffects during therapy with sulfonylureas and biguanides.

  1985cited by this paper
• Streptozotocin and alloxan induce DNA strand breaks and poly(ADP–ribose) synthetase in pancreatic islets

  1981cited by this paper

• Hypoglycemia and Hypolipidemia Assisted Nephroprotective Potential of Hygrophila auriculata (K. Schum) Heine in Streptozotocin/Nicotinamide Rodent Model of Type 2 Diabetes

  2024cites this paper
• Na+/H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium‐glucose co‐transporter 1‐mediated glucose absorption in the small intestine

  2018cites this paper
• 2型糖尿病患者におけるシタグリプチン50 mgから100 mgへの増量とミチグリニドカルシウム水和物・ボグリボースへの切り替えにおける有用性に関する比較検討

  2017cites this paper
• Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes.

  2017cites this paper
• Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats

  2014cites this paper
• Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).

  2013cites this paper
• SGLT inhibitors as new therapeutic tools in the treatment of diabetes.

  2011cites this paper
• Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction.

  2009cites this paper
• Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.

  2009cites this paper
• Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

  2009cites this paper
• Hypoglycaemic effects of antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic rats.

  2008cites this paper
• Effects of Antidiabetic Drugs on Glucose Tolerance in Streptozotocin-nicotinamide-induced Mildly Diabetic and Streptozotocin-induced Severely Diabetic Mice

  2008cites this paper
• Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients

  2008cites this paper
• Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level

  2007cites this paper
• Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats

  2006cites this paper
• [Animal models of diabetes and development of anti-diabetic agents].

  2006cites this paper
• Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic β‐cells

  2005cites this paper
• Exenatide: a novel treatment of Type 2 diabetes

  2005cites this paper
• Novel strategies for the pharmacological management of type 2 diabetes.

  2004cites this paper
• Mitiglinide

  2004cites this paper